BGI Genomics Co Ltd (300676)
Shenzhen Stock Exchange · China · prices in CNY · close of 20 Oct 2026
Key indicators
| Last close | CNY 41.98 |
|---|---|
| 52-week range | 32.55 – 65.00 |
| Return, 1 month / 3 months | +17.0% / +12.3% |
| Return, 1 year / 3 years | −13.9% / −21.6% |
| Trend | Uptrend |
| RSI (14) | 52 |
| Volatility (1 year) | 42.1% |
| Worst drawdown (1 year) | -44.5% |
| Average daily value traded | 462.98M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BGI Genomics is a Chinese life-science company based in Shenzhen that provides genetic sequencing and testing services. It offers clinical genetic tests, including prenatal screening and testing for inherited conditions and cancer, along with research sequencing services for hospitals, laboratories, universities and other institutions. The company also supplies related reagents and laboratory equipment, and it works with healthcare providers and research organisations in China and other markets around the world.
BGI Genomics Co Ltd trades under the code 300676 on the Shenzhen Stock Exchange in China, with its price quoted in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
BGI Genomics Co Ltd (300676) trades on the Shenzhen Stock Exchange in China. It last closed at CNY 41.98 on 20 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a strong price profile), ranking 299 of 2,821 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 13.9% and over the last three months it rose 12.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shenzhen Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 0.8% | ||
| From 52-week high | -29.1% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 12.3% | ||
| 6-month return | 5.4% | ||
| 12-month return, skipping the last month | -26.4% | ||
| Stability (higher is calmer) | 60 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 42.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -44.5% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 462.98M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.3% |
|---|---|
| 1 month | +17.0% |
| 3 months | +12.3% |
| 6 months | +5.4% |
| 1 year | −13.9% |
| 3 years | −21.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 40.34 / 41.63 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.36 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 Jul 2024 | CNY 0.1000 |
| 7 Jun 2023 | CNY 1.0000 |
| 6 Jul 2022 | CNY 0.3500 |
| 7 Jul 2021 | CNY 0.3500 |
| 7 Jul 2020 | CNY 0.1010 |
| 13 Jun 2019 | CNY 0.1000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shenzhen Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.